The colectomy-focused surgical device developer, which counts SinoPharm as an earlier investor, has secured series B-plus funding, in a round led by Bluestem Capital.

Virtual Incision, a US-based robotic surgery device developer backed by pharmaceutical company SinoPharm, received $20m yesterday in a series B-plus round led by venture capital firm Bluestem Capital. VC firms PrairieGold Venture Partners and Genesis Innovation Group joined unnamed affiliated investors in the round, which incorporated $1m in debt financing from Bluestem Capital and PrairieGold…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.